News & Events
-
Watch HOPE Summit 2026 Videos
HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well with lung cancer.
For...
-
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung... -
Podcast: Lung Cancer Diagnosis—What Happens Next
What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from... -
Podcast: Why Community Matters in Lung Cancer Care
Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to... -
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who... -
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their... -
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
KRAS Virtual Meetup
Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. After registering, you will receive a confirmation email... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting...
Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios
Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios
New Findings in Non-Small Cell Lung Cancer Described from JSS Science and Technology University (Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant...
New Findings in Non-Small Cell Lung Cancer Described from JSS Science and Technology University (Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant...
New Findings from University of Granada in the Area of Anticancer Agents Reported (Development of mitochondria-targeted isoquinolinium derivatives with dual fluorescence and anticancer activity against...
New Findings from University of Granada in the Area of Anticancer Agents Reported (Development of mitochondria-targeted isoquinolinium derivatives with dual fluorescence and anticancer activity against...
Expanding First-Line NSCLC Options: GenFleet Therapeutics Announces GFH375, Oral KRAS G12D (ON/OFF) Inhibitor, Advances into a Phase II Study Evaluating Monotherapy and Combination Regimens with...
Expanding First-Line NSCLC Options: GenFleet Therapeutics Announces GFH375, Oral KRAS G12D (ON/OFF) Inhibitor, Advances into a Phase II Study Evaluating Monotherapy and Combination Regimens with...
Genfleet Therapeutics-B (02595): GFH375 (an oral KRAS G12D inhibitor) has entered a Phase II study for first-line treatment of non-small cell lung cancer, exploring multiple therapeutic regimens including monotherapy, combination with EGFR monoclonal anti
Genfleet Therapeutics-B (02595): GFH375 (an oral KRAS G12D inhibitor) has entered a Phase II study for first-line treatment of non-small cell lung cancer, exploring multiple therapeutic regimens including monotherapy, combination with EGFR monoclonal anti
Jacobio Pharma Reports Profit Turnaround in 2026 Interim Results, Continues to Build Its KRAS Franchise
Jacobio Pharma Reports Profit Turnaround in 2026 Interim Results, Continues to Build Its KRAS Franchise
Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC
Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study
Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study
Clinical presentation and outcomes according to KRAS status in advanced non-small cell lung cancer
Clinical presentation and outcomes according to KRAS status in advanced non-small cell lung cancer